MARKET

IQV

IQV

Iqvia Hldgs Inc
NYSE
233.98
-6.86
-2.85%
After Hours: 233.98 0 0.00% 16:37 04/25 EDT
OPEN
239.32
PREV CLOSE
240.84
HIGH
239.89
LOW
232.42
VOLUME
1.06M
TURNOVER
0
52 WEEK HIGH
261.73
52 WEEK LOW
167.42
MARKET CAP
42.59B
P/E (TTM)
32.10
1D
5D
1M
3M
1Y
5Y
Is It Time To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)?
IQVIA Holdings Inc. Saw a double-digit share price rise of over 10% in the past couple of months. The company's shares are still trading at a fairly cheap price of $334.65 on the NYSE. IQVIA is expected to grow its profit by 36% over the next couple of years. Its future growth isn't fully reflected in the company's share price yet. This indicates a potential opportunity to buy the stock at a low price. We look at IQvIA's outlook and valuation to see if the opportunity still exists.
Simply Wall St · 1d ago
Medpace raised to Buy at Jefferies after Q1 earnings beat
Healthcare Medpace raised to Buy at Jefferies after Q1 earnings beat on Tuesday. Contract research organization exceeded Street forecasts with its Q1 2024 earnings. Jefferies upgraded Medpace Holdings to Buy from Hold after the company topped consensus on earnings. The analyst also raised his price target to $450 from $340.
Seeking Alpha · 2d ago
Weekly Report: what happened at IQV last week (0415-0419)?
Weekly Report · 4d ago
Bank of America Securities Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
TipRanks · 04/17 14:35
Press Release: IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
IQVIA to announce its first-quarter 2024 financial results on May 2, 2024. The company will also host a conference call and webcast at 9:00 a.m. Eastern Time. IQVIA is a leading provider of advanced analytics, technology solutions to the life sciences industry.
Dow Jones · 04/15 20:20
Weekly Report: what happened at IQV last week (0408-0412)?
Weekly Report · 04/15 09:16
AbbVie keeps Humira market share near 100% despite biosimilars: report
Healthcare AbbVie keeps Humira market share near 100% despite biosimilars: report. Humira is the world's bestselling drug for the 10th year in a row. Amgen launched the first biosimilar version of the arthritis drug in the U.S. Last year.
Seeking Alpha · 04/13 14:52
IQVIA HOLDINGS INC <IQV.N>: MIZUHO RAISES TARGET PRICE TO $277 FROM $268
Reuters · 04/11 11:46
More
About IQV
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.

Webull offers Iqvia Holdings Inc stock information, including NYSE: IQV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IQV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IQV stock methods without spending real money on the virtual paper trading platform.